BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35157906)

  • 1. Indoleamine 2,3-dioxygenase 1 regulates breast cancer tamoxifen resistance through interleukin-6/signal transducer and activator of transcription.
    Zhao X; Jiang Y; Xu M; Hu J; Feng N; Deng H; Lu C; Huang T
    Toxicol Appl Pharmacol; 2022 Apr; 440():115921. PubMed ID: 35157906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
    Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
    Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
    Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
    J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of AKR1 family in tamoxifen resistant invasive lobular breast cancer based on data mining.
    Xu D; Zhang Y; Jin F
    BMC Cancer; 2021 Dec; 21(1):1321. PubMed ID: 34886806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POR overexpression induces tamoxifen-resistance in breast cancer through the STAT1/c-Myc pathway.
    Chen S; Wu D; Liu Q; Jin F; Yao F; Fang Y
    Mol Carcinog; 2023 Feb; 62(2):249-260. PubMed ID: 36321415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-associated macrophages secrete CC-chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer.
    Li D; Ji H; Niu X; Yin L; Wang Y; Gu Y; Wang J; Zhou X; Zhang H; Zhang Q
    Cancer Sci; 2020 Jan; 111(1):47-58. PubMed ID: 31710162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
    Xiong H; Jin X; You C
    Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
    Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
    Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
    Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
    Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers.
    Noonepalle SK; Gu F; Lee EJ; Choi JH; Han Q; Kim J; Ouzounova M; Shull AY; Pei L; Hsu PY; Kolhe R; Shi F; Choi J; Chiou K; Huang TH; Korkaya H; Deng L; Xin HB; Huang S; Thangaraju M; Sreekumar A; Ambs S; Tang SC; Munn DH; Shi H
    Cancer Immunol Res; 2017 Apr; 5(4):330-344. PubMed ID: 28264810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAT3 Signaling Axis and Tamoxifen in Breast Cancer: A Promising Target for Treatment Resistance.
    Zamanian MY; Golmohammadi M; Alalak A; Kamiab Z; Obaid R; Ramírez-Coronel AA; Hjazi A; Abosaooda M; Mustafa Y; Heidari M; Verma A; Nazari Y; Bazmandegan G
    Anticancer Agents Med Chem; 2023; 23(16):1819-1828. PubMed ID: 37448364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming Tamoxifen Resistance by Regulation of Del-1 in Breast Cancer.
    Lee J; Jeong JH; Jung JH; Kim WW; Lee SJ; Park JY; Park JY; Kang SH; Kim EA; Park JH; Chae YS; Park HY
    Oncology; 2019; 97(3):180-188. PubMed ID: 31330520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SIRT4 enhances the sensitivity of ER-positive breast cancer to tamoxifen by inhibiting the IL-6/STAT3 signal pathway.
    Xing J; Li J; Fu L; Gai J; Guan J; Li Q
    Cancer Med; 2019 Nov; 8(16):7086-7097. PubMed ID: 31573734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells.
    Riggs KA; Wickramasinghe NS; Cochrum RK; Watts MB; Klinge CM
    Cancer Res; 2006 Oct; 66(20):10188-98. PubMed ID: 17047084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.
    Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F
    Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.
    Heckler MM; Thakor H; Schafer CC; Riggins RB
    FEBS J; 2014 May; 281(10):2431-42. PubMed ID: 24684682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of TMEM47 Induces Tamoxifen Resistance in Human Breast Cancer Cells.
    Men X; Su M; Ma J; Mou Y; Dai P; Chen C; Cheng XA
    Technol Cancer Res Treat; 2021; 20():15330338211004916. PubMed ID: 33745390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.